专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08440689B2 Fused heteroaromatic pyrrolidinones 有权
公开(公告)号：US08440689B2
公开(公告)日：2013-05-14
申请号：US12972333
申请日：2010-12-17
申请人： Yasuyoshi Arikawa , Qing Dong , Victoria Feher , Benjamin Jones , Betty Lam , Zhe Nie , Christopher Smith , Masashi Takahashi
发明人： Yasuyoshi Arikawa , Qing Dong , Victoria Feher , Benjamin Jones , Betty Lam , Zhe Nie , Christopher Smith , Masashi Takahashi
IPC分类号： C07D471/04 , A61K31/437 , A61P11/06 , A61P19/02 , A61P17/06 , A61P35/00 , C07D487/04 , A61K31/519
CPC分类号： C07D487/04 , A61K31/437 , A61K31/519 , A61K31/527 , A61K45/06 , C07D471/04 , C07D487/10 , C07D519/00
摘要： Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

2. 发明授权

US09181255B2 Fused heteroaromatic pyrrolidinones as SYK inhibitors 有权
标题翻译：融合的杂芳族吡咯烷酮作为SYK抑制剂
公开(公告)号：US09181255B2
公开(公告)日：2015-11-10
申请号：US13518806
申请日：2010-12-17
申请人： Yasuyoshi Arikawa , Benjamin Jones , Betty Lam , Zhe Nie , Christopher Smith , Masashi Takahashi , Qing Dong , Victoria Feher
发明人： Yasuyoshi Arikawa , Benjamin Jones , Betty Lam , Zhe Nie , Christopher Smith , Masashi Takahashi , Qing Dong , Victoria Feher
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P29/00 , A61P11/06 , A61P17/06 , A61P25/28 , C07D471/04 , A61K31/437 , A61K31/527 , A61K45/06 , C07D487/10 , C07D519/00
CPC分类号： C07D487/04 , A61K31/437 , A61K31/519 , A61K31/527 , A61K45/06 , C07D471/04 , C07D487/10 , C07D519/00
摘要： Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
摘要翻译：公开了式1的化合物及其药学上可接受的盐，其中G，L1，L2，R1，R2，R3和R4在说明书中定义。本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗涉及免疫系统和炎症的疾病，疾病和病症的用途，包括类风湿性关节炎，血液恶性肿瘤，上皮癌（即，癌症）以及其它疾病，疾病和表示SYK抑制的病症。

3. 发明申请

US20130116260A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS 有权
标题翻译：作为SYK抑制剂的FUSED HETEROAROMATIC PYRROLIDINONES
公开(公告)号：US20130116260A1
公开(公告)日：2013-05-09
申请号：US13518806
申请日：2010-12-17
申请人： Yasuyoshi Arikawa , Benjamin Jones , Betty Lam , Zhe Nie , Christopher Smith , Masashi Takahashi , Qing Dong , Victoria Feher
发明人： Yasuyoshi Arikawa , Benjamin Jones , Betty Lam , Zhe Nie , Christopher Smith , Masashi Takahashi , Qing Dong , Victoria Feher
IPC分类号： A61K31/527 , A61K45/06 , C07D471/04 , C07D487/10 , C07D487/04 , A61K31/519
CPC分类号： C07D487/04 , A61K31/437 , A61K31/519 , A61K31/527 , A61K45/06 , C07D471/04 , C07D487/10 , C07D519/00
摘要： Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
摘要翻译：公开了式1的化合物及其药学上可接受的盐，其中G，L1，L2，R1，R2，R3和R4在说明书中定义。本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗涉及免疫系统和炎症的疾病，疾病和病症的用途，包括类风湿性关节炎，血液恶性肿瘤，上皮癌（即，癌症）以及其它疾病，疾病和表示SYK抑制的病症。

4. 发明申请

US20110152273A1 FUSED HETEROAROMATIC PYRROLIDINONES 有权
标题翻译：熔化的异辛基吡咯烷酮
公开(公告)号：US20110152273A1
公开(公告)日：2011-06-23
申请号：US12972333
申请日：2010-12-17
申请人： Yasuyoshi Arikawa , Qing Dong , Victoria Feher , Benjamin Jones , Betty Lam , Zhe Nie , Christopher Smith , Masashi Takahashi
发明人： Yasuyoshi Arikawa , Qing Dong , Victoria Feher , Benjamin Jones , Betty Lam , Zhe Nie , Christopher Smith , Masashi Takahashi
IPC分类号： A61K31/519 , C07D487/04 , C07D471/04 , A61K31/437 , A61P35/00 , A61P29/00 , A61P11/08 , A61P11/06 , A61P17/06 , A61P7/02
CPC分类号： C07D487/04 , A61K31/437 , A61K31/519 , A61K31/527 , A61K45/06 , C07D471/04 , C07D487/10 , C07D519/00
摘要： Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
摘要翻译：公开了式1的化合物及其药学上可接受的盐，其中G，L1，L2，R1，R2，R3和R4在说明书中定义。本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗涉及免疫系统和炎症的疾病，疾病和病症的用途，包括类风湿性关节炎，血液恶性肿瘤，上皮癌（即，癌症）以及其它疾病，疾病和表示SYK抑制的病症。

5. 发明申请

US20100204471A1 MAPK/ERK KINASE INHIBITORS 审中-公开
标题翻译： MAPK / ERK激酶抑制剂
公开(公告)号：US20100204471A1
公开(公告)日：2010-08-12
申请号：US12446974
申请日：2007-10-22
申请人： Qing Dong , Victoria Feher , Stephen W. Kaldor , Naoki Tomita
发明人： Qing Dong , Victoria Feher , Stephen W. Kaldor , Naoki Tomita
IPC分类号： C07D413/02 , C07D239/10 , C07D405/02
CPC分类号： C07D239/545 , C07D239/557 , C07D401/12 , C07D403/06 , C07D405/12 , C07D413/06
摘要： Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
摘要翻译：提供化合物，药物组合物，试剂盒和方法用于包含选自以下的化合物的MEK：其中变量如本文所定义。

6. 发明授权

US08600566B1 Thermal management smart valve with rupture detection and isolation 失效
标题翻译：具有破裂检测和隔离的热管理智能阀
公开(公告)号：US08600566B1
公开(公告)日：2013-12-03
申请号：US13021580
申请日：2011-02-04
申请人： Donald R. Longo , Donald D. Dalessandro , Qing Dong , Frank T. Ferrese , John M. Roach , Michael G. Zink
发明人： Donald R. Longo , Donald D. Dalessandro , Qing Dong , Frank T. Ferrese , John M. Roach , Michael G. Zink
IPC分类号： G05D7/00
CPC分类号： F17D5/00 , F16K37/0075 , F17D3/18 , F17D5/005 , G01M3/00
摘要： The condition of a fluid piping system is monitored by multiple intercommunicative smart valves, each executing a computer algorithm that designates smart valves as critical or non-critical, compares measurement data versus simulation data, and makes decisions based on the critical-or-noncritical designations and the measurement-versus-simulation comparisons. Initial measurement-versus-simulation comparisons are made for downstream pressure, flow rate, and temperature. If a measurement-versus-simulation discrepancy is found in either the downstream pressure or the flow rate, then the algorithm compares a measurement rupture determinant versus a simulation rupture determinant; if a measurement-versus-simulation discrepancy is found in the rupture determinant, then the smart valve is closed. If a measurement-versus-simulation discrepancy is found in the temperature, then the smart valve, if non-critical, is closed; however, if the smart valve is critical, then the nearest upstream non-critical smart valve is closed. Any measurement-versus-simulation discrepancy results, at least, in an alarm or warning.
摘要翻译：流体管道系统的状况由多个互通智能阀监控，每个执行一个将智能阀指定为关键或非关键的计算机算法，将测量数据与模拟数据进行比较，并根据关键或非关键指标进行决策和测量与模拟的比较。对下游压力，流量和温度进行初始测量与模拟比较。如果在下游压力或流速中发现测量与模拟的差异，则该算法将测量断裂行为与模拟破裂行列式进行比较; 如果在断裂决定因素中发现测量与模拟的差异，则智能阀关闭。如果在温度中发现测量与模拟的差异，则智能阀（如果不重要）关闭; 然而，如果智能阀是关键的，则最近的上游非关键智能阀关闭。至少在报警或警告中，任何测量与模拟的差异都会产生。

7. 发明授权

US08509060B1 Active-avoidance-based routing in a wireless ad hoc network 失效
标题翻译：无线自组织网络中基于主动回避的路由
公开(公告)号：US08509060B1
公开(公告)日：2013-08-13
申请号：US13172137
申请日：2011-06-29
申请人： Qing Dong , Albert Ortiz , Donald D. Dalessandro , David J. Kocsik
发明人： Qing Dong , Albert Ortiz , Donald D. Dalessandro , David J. Kocsik
IPC分类号： H04J1/16 , H04L12/28 , G06F15/173 , H04L12/56
CPC分类号： H04L45/28 , H04L45/02 , H04L45/12 , H04W40/205
摘要： Conventional multi-hop routing of ad hoc wireless networks involves considerations such as costs, connection quality, distances, and numbers of hops. A conventional wireless routing algorithm may fail when a destructive event takes place and is rapidly expanding in area, as the route discoveries may perpetually lag behind the rate of expansion of the destructive area. As typically embodied, the present invention's wireless routing algorithm detects a destructive event early, assumes rapid expansion of the destruction area, establishes “subnets” of nodes, and predetermines one or more routes that circumvent the rapidly expanding destruction area by exiting from and returning to the subnet in which the destructive event originates. Typical inventive practice avails itself of the architectural character of the physical setting for the wireless network, for instance by establishing subnets corresponding to compartments formed by wall-like structures (e.g., shipboard bulkheads), which represent natural barriers to expansion of a destruction area.
摘要翻译： ad hoc无线网络的传统多跳路由涉及诸如成本，连接质量，距离和跳数的考虑。传统的无线路由算法可能在破坏性事件发生并且在区域中迅速扩大时失败，因为路由发现可能永久落后于破坏性区域的扩展速率。如通常实施的，本发明的无线路由算法早期检测到破坏性事件，假定破坏区域的快速扩展，建立节点的“子网”，并且通过退出并返回到预定义来规避快速扩大的破坏区域的一个或多个路由破坏性事件起源的子网。典型的创造性实践利用了无线网络的物理设置的架构特征，例如通过建立对应于由壁状结构（例如，船上舱壁）形成的隔间的子网，其代表破坏区域的扩展的自然障碍。

8. 发明申请

US20120095233A1 KINASE INHIBITORS 失效
标题翻译：激酶抑制剂
公开(公告)号：US20120095233A1
公开(公告)日：2012-04-19
申请号：US12103882
申请日：2008-04-16
申请人： Jason W. Brown , Qing Dong , Bheema R. Paraselli , Jeffrey A. Stafford , Michael B. Wallace , Hasanthi Wijesekera , Nicholas Scorah
发明人： Jason W. Brown , Qing Dong , Bheema R. Paraselli , Jeffrey A. Stafford , Michael B. Wallace , Hasanthi Wijesekera , Nicholas Scorah
IPC分类号： C07D471/04 , C07D209/88
CPC分类号： C07D471/14 , C07D241/18 , C07D401/12 , C07D471/04 , C07D487/04
摘要： Compounds are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
摘要翻译：提供化合物用于与包含选自以下的化合物的激酶一起使用：其中变量如本文所定义。还提供了包含这些化合物的药物组合物，试剂盒和制品; 用于制备化合物的方法和中间体; 以及使用所述化合物的方法。

9. 发明授权

US08119655B2 Kinase inhibitors 失效
公开(公告)号：US08119655B2
公开(公告)日：2012-02-21
申请号：US11539857
申请日：2006-10-09
申请人： Qing Dong , Bheema R. Paraselli , Nicholas Scorah , Jeffrey A. Stafford , Michael B. Wallace
发明人： Qing Dong , Bheema R. Paraselli , Nicholas Scorah , Jeffrey A. Stafford , Michael B. Wallace
IPC分类号： A61K31/437 , C07D471/04
CPC分类号： C07D471/04 , C07D471/12 , C07D487/04 , C07D487/14
摘要： Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

10. 发明授权

US07855288B2 Pyrrolo [1,2-d] [1,2-4] triazine as inhibitors of c-Jun N terminal kinases (JNK) and p-38 kinases 失效
标题翻译：吡咯并[1,2-d] [1,2-4]三嗪作为c-Jun N末端激酶（JNK）和p-38激酶的抑制剂
公开(公告)号：US07855288B2
公开(公告)日：2010-12-21
申请号：US11576301
申请日：2005-10-25
申请人： Qing Dong
发明人： Qing Dong
IPC分类号： C07D487/04 , A61K31/53 , A61P19/02 , A61P1/00
CPC分类号： C07D487/04
摘要： A compound of formula (I): wherein the substituents are as defined in the specification as inhibitor of C-Jun N terminal Kinases (JNK) and P-38 Kinases.
摘要翻译：式（I）的化合物：其中取代基如说明书中所定义为C-Jun N末端激酶（JNK）和P-38激酶的抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式